Skip to main content
SpringerLink
Log in

(Potentielle) Antipsychotika mit neuartigen Wirkmechanismen

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 22 Accesses

Zusammenfassung

Nur ein Teil der paranoid-halluzinatorischen Patienten profitiert von der neuroleptischen Therapie, denn die bislang verfügbaren Neuroleptika wirken hauptsächlich gegen akute produktiv-psychotische Symptome, sind jedoch wenig effektiv bei Negativ-Symptomatik (Angrust et al. 1980) und zeigen insbesondere bei chronischen Residualzuständen eine ungenügende Wirkung. Die häufig auftretenden extrapyramidalen Nebenwirkungen einschließlich der nach längerer Zeit gehäuften tardiven Dyskinesie stellen weitere schwere Nachteile der neuroleptischen Therapie dar. Die Notwendigkeit neuerer und besserer Antipsychotika ist offensichtlich.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abbott A (1990) 5-HT3 antagonists and ligands for dopamine Dl and autoreceptors offer new leads for antipsychotic drugs. Trends Pharmacol Sci 11: 49–51

    Article  PubMed  CAS  Google Scholar 

  • Allen RM, Young Sj (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135: 1081–1084

    PubMed  CAS  Google Scholar 

  • Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17–19

    Article  PubMed  CAS  Google Scholar 

  • Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI (1986) Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 143: 650–651

    PubMed  CAS  Google Scholar 

  • Arana GW, Ornsteen ML, Kantner F, Friedman HL, Greenblatt DJ, Shader RI (1986) Benzodiazepines — New indications. Psychopharmacol Bull 22: 77–87

    PubMed  CAS  Google Scholar 

  • Barnes JM, Barnes NM, Costall B, Domeney AM, Kelly ME, Naylor RJ (1990) 5-HT3 Receptor antagonists as possible antipsychotics. In: Stefanis CN, Soldatos CR, Rabavilas AD (eds) Psychiatry: a world perspective, vol 2. Elsevier, Amsterdam, pp 677-682

    Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Cuff Ther Res 40: 492–499

    Google Scholar 

  • Bersani G, Bressa GM, Meco G, Marini S, POZZI F (1990) Combined serotonin 5-HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64766). Hum Psychopharmacol 5: 225–231

    Article  Google Scholar 

  • Bischoff S, Vassout A, Delini-Stula A, Waldmeier P (1986) Interactions of cipazoxapine, citatepine, eresepine, and maroxepine with central dopamine (DA) receptors: effects on in vivo (3H)spiperone binding, DA metabolism, and behavioral parameters. Pharmacopsychiatry 19: 306–307

    Google Scholar 

  • Bissei lE G, Nemeroff CB (1988) Neurotensin and the mesocorticolimbic dopamine system. In: Kalivas PW, Nemeroff CB (eds) The mesocorticolimbic dopamine system. Ann N Y Acad Sci 537: 397–404

    Google Scholar 

  • Bowen WD, Kirschner BN, Newman AH, Rice KC (1988) 6 Receptors negatively modulate ago- nist-stimulated phosphoinositide metabolism in rat brain. Eur J Pharmacol 149: 399-400

    Google Scholar 

  • Cantrell BE, Leander JD, Mendelsohn LG, Schoepp DD, Hermann RB, Immerman DM (1988) The search for a PCP antagonist: the discovery of potent PCP-like activity in hexahydroinde- no(2,1-c)pyridine series of compounds. In: DOMINO EF, KAMENKA J-M (eds) Sigma and phen- cyclidine-like compounds as molecular pro- bes in biology. NPP Books, Ann Arbour, pp 11–17

    Google Scholar 

  • Chipkin RE (1990) D1-antagonist in clinical trial. Trends Pharmacol Sci 11: 185

    Article  PubMed  CAS  Google Scholar 

  • Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH23390 in reserpinized rats suggests a common mechanism of action. Eur J Pharmacol 136: 371–375

    Article  PubMed  CAS  Google Scholar 

  • Chipkin RE, loRIO LC, Coffin VL, Mcquade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D-1 selective benzonaphthazepine with potential anti-psychotic activity. J Pharmacol Exp Ther 247: 1093–1102

    PubMed  CAS  Google Scholar 

  • Christensson E, BJöix A (1990) Amperozide: a new pharmacological approach in the treatment of schizophrenia. Pharmacol Toxicol [Suppll 1: 5–7

    Article  Google Scholar 

  • Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859–868

    Google Scholar 

  • Costall B, Domeny AM, Naylor RJ (1990) 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat. Neuro Report 1: 77–80

    Google Scholar 

  • Coward D, Dixon K, Enz A, Shearman G, Urwyler S, White T, Karobath M (1989) Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 25: 393–397

    PubMed  CAS  Google Scholar 

  • Delini-Stula A (1986) Neuroanatomical, neuro-pharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry 19: 134–139

    Article  PubMed  CAS  Google Scholar 

  • Del Zompo M, Bocchetta A, PICCARDI MP, Corsini GU (1986) Dopamine agonists in the treatment of schizophrenia. In: VAN REE JM, MATTHYSSE S (eds) Progress in brain research, vol 65. Elsevier, Amsterdam, pp 41–48

    Google Scholar 

  • De Wied D (1979) Schizophrenia as an inborn error in the degradation of ß-endorphin — a hypothesis. Trends Neurosci 2: 79–82

    Article  Google Scholar 

  • De Wied D, Kovacs GL, Bohus B, van Ree JM, Greven HM (1978) Neuroleptic activity of the neuropeptide ß-LPH62–77 ([des-Tyr’]-y-endorphin; DTyE ). Eur J Pharmacol 49: 427–436

    Google Scholar 

  • Dieterle D, Müller-Spahn F, Ackenheil M (1988) Comparison of zotepine and perazine in schi- zophrenia. Psychopharmacology 96 [Suppll: 340

    Google Scholar 

  • Dose M, Apelt S, Emrich HM (1987) Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 22: 303–310

    Google Scholar 

  • Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94: 1–7

    Article  PubMed  CAS  Google Scholar 

  • Ferris RM, Tang FLM, Chang K J, Russell A (1986) Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, com- petitive antagonist of sigma sites in brain. Life Sci 38: 2329–2337

    Article  PubMed  CAS  Google Scholar 

  • Fink H, Morgenstern R, Oelssner W (1984) Ciozapine — a serotonin antagonist? Pharmacol Biochem Behav 20: 513–517

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppäck CH (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25: 97–100

    PubMed  CAS  Google Scholar 

  • Foster AC, Fagg GE (1987) Taking apart NMDA receptors. Nature 329: 395–396

    Article  PubMed  CAS  Google Scholar 

  • Gelders YG (1990) Die Bedeutung des 5-HT2- Rezeptor-Antagonismus für die Behandlung der Schizophrenie, unter spezieller Berücksichtigung der Minussymptomatik. In: Müller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 223–230

    Chapter  Google Scholar 

  • Gelders YG, Vanden Bussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9 (S4): 325–327

    Google Scholar 

  • Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23: 206–211

    Article  PubMed  CAS  Google Scholar 

  • Gerbaldo H, Demisch L, Lehmann C-O, Bochnik J (1988) The effect of OPC-4392, a partial dopa- mine receptor agonist, on negative symptoms: results of an open study. Pharmacopsychiatry 21: 387–388

    Google Scholar 

  • Gunne L-M, Lindstrom L, Terenius L (1977) Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm 40: 13–19

    Article  PubMed  CAS  Google Scholar 

  • Hietala J, Lappalainen J, Koulu M, Syvälahti E (1990) Dopamine D, receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? Trends Pharmacol Sci 11: 406–410

    Article  PubMed  CAS  Google Scholar 

  • Hökfelt T, Rehfeld JF, Skirboll LR, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285: 476–478

    Article  PubMed  Google Scholar 

  • Hökfelt T, Everitt BJ, Theodorsson-Norheim E, Goldstein M (1984) Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J Comp Neurol 222: 543–559

    Article  PubMed  Google Scholar 

  • Janowsky A, Berger SP (1989) Clozapine inhibits [3H]MK-801 binding to the glutamate receptor-ion channel complex. Schizophr Res 2: 189

    Article  Google Scholar 

  • Kidron R, Averbuch I, Klein E, Belmaker RH (1985) Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 20: 199–228

    Article  Google Scholar 

  • Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382

    Google Scholar 

  • Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenie. Nervenarzt 55: 602–606

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Mack-Burkhardt F, Riederer P (1989a) Regional distribution of [’FINK-801 binding sites in the human brain. Brain Res 489: 397399

    Google Scholar 

  • Kornhuber J, Mack-Burkhardt F, Riederer P, Heben-Streit GF, Reynolds GP, Andrews HB, Beckmann H (1989b) [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236

    Google Scholar 

  • Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E (1989c) 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 75: 1–10

    Google Scholar 

  • Kostowski W, Gumulka W, Czlonkowski A (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 48: 443–446

    Article  PubMed  CAS  Google Scholar 

  • Largent BL, Wikström H, Snowman AM, Snyder SH (1988) Novel antipsychotic drugs share high affinity for 6 receptors. Eur J Pharmacol 155: 345–347

    Google Scholar 

  • Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophreno- mimetic drug — Sernyl. Arch Neurol Psychiat 81: 363–369

    CAS  Google Scholar 

  • Matussek N (ed) (1987) Pharmacopsychiatry. Special Issue I, 20: 1–74

    Google Scholar 

  • Mclean S, Weber E (1988) Autoradiographie visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 25: 259–269

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamineserotonin hypothesis of schizophrenia. Psychopharmacology 99: S18 - S27

    Article  PubMed  Google Scholar 

  • Meltzer HY, Matsubara S, Lee J-C (1989) Classifi-cation of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pk. values. J Pharmacol Exp Ther 251: 238–246

    PubMed  CAS  Google Scholar 

  • Mesotten F, Sin E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 99: 445–449

    Article  PubMed  CAS  Google Scholar 

  • Miller R, Wickens JR, Beninger RJ (1990) Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Prog Neurobiol 34: 143–183

    Article  PubMed  CAS  Google Scholar 

  • Möller HJ, Kissling W, Dietzfelbinger T, Stol K-D, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry 22: 38–41

    Article  PubMed  Google Scholar 

  • Mueser KT, Dysken MW (1983) Narcotic antagonists in schizophrenia: a methodological review. Schizophr Bull 9: 213–225

    Google Scholar 

  • Musacchio JM (1990) The psychotomimetic effects of opiates and the 6 receptor. Neuropsychopharmacology 3: 191–200

    PubMed  CAS  Google Scholar 

  • Musch B, Maillard F, Louvel E (1989) The effect of RP 54274, an antagonist of the glutamatergic transmission in “negative type” schizophrenia. ( Abstract) ECNP, Göteborg 1989, p66

    Google Scholar 

  • Naber D, Gaussares C, Moeglen JM, Tremmel L, Bailey PE (1991) Wirksamkeit und Verträglichkeit des Dopamin-Agonisten/ Antagonisten SDZ HDC 912 in der Therapie schizophrener Patienten. In: LAUX G, GAEBEL W (Hrsg) Biologische Psychiatrie — Synopsis 1990/91. Springer, Berlin Heidelberg New York Tokyo (im Druck)

    Google Scholar 

  • Nair NPV, Lai. S, Bloom DM (1986) Cholecystokinin and schizophrenia. In: van Ree JM, Matthysse S (eds) Progress in brain research, vol 65. Elsevier, Amsterdam, pp 237–258

    Google Scholar 

  • Nemeroff CB, Cain ST (1985) Neurotensin-dopamine interactions in the CNS. Trends Pharmacol Sci 201–205

    Google Scholar 

  • Nemeroff CB, BISSETn: G (1988) Neuropeptides, dopamine, and schizophrenia. In: KALIVAS PW

    Google Scholar 

  • Nemeroff CB (eds) The mesocorticolimbic do- pamine system. Ann NY Acad Sci 537: 273–291

    Google Scholar 

  • Nemeroff CB, YOUNGBLOOD W, MANBERG PJ, PRANGE AJ, KIZER JS (1983) Regional brain concentrations of neuropeptides in Huntington’s chorea and schizophrenia. Science 221: 972–975

    Article  PubMed  CAS  Google Scholar 

  • Niemegeers CJE, Awouters F, Janssen PAJ (1990) Pharmakologie der Neuroleptika und relevante Mechanismen zur Behandlung von Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 185197

    Google Scholar 

  • Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia. Pharmacopsychiatry 21: 389–390

    Article  PubMed  CAS  Google Scholar 

  • Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm [GenSect] 84: 233–236

    Article  CAS  Google Scholar 

  • Pichot P, Boyer P (1989) A controlled double-blind multi-centre trial of high dose amisulpride versus haloperidol in acute psychotic states. In: Bornstein P et al. (eds) Amisulpride. Expansion Scientific Francaise, Paris, pp 8392

    Google Scholar 

  • Pradhan SN (1984) Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8: 493–501

    Article  PubMed  CAS  Google Scholar 

  • Quirion R, Chichportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, Woods IH, Zukin SR (1987) Classification and nomenclature of phencyclidine and 6 receptor sites. Trends Neurosci 10: 444–446

    Article  CAS  Google Scholar 

  • Reyntjens AJM, Gelders YG, Hoppenbrouwers MLJA, Vanden Bussche G (1986) Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8: 205–211

    Article  CAS  Google Scholar 

  • Rosse RB, Theut SK, Banay-Sciwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12: 416–424

    Article  PubMed  CAS  Google Scholar 

  • Ruther E, Eben E, Klein H, Nedopil N, Dieterle D, Hippius H (1989) Comparative double-blind study of amisulpride and haloperidol in the treatment of acute episodes of positive schizophrenia. In: BORNSTEIN P et al. (eds) Amisulpride. Expansion Scientific Francaise, Paris, pp 63–72

    Google Scholar 

  • Schnitzler A, Klieser E, Lehmann E, Wurthmann C, Lemmer W (1991) Wirksamkeit und Verträglichkeit von Risperidon im Vergleich zu Clozapin in der Behandlung akut schizophrener Patienten. In: GAEBEL W, LAUx G (Hrsg) Biologische Psychiatrie - Synopsis 1990/91. Springer, Berlin Heidelberg New York Tokyo (im Druck)

    Google Scholar 

  • Sedvall G (ed) (1990) Development of a new antipsychotic-Remoxipride. Acta Psychiatr Scand [Suppl 358] 82: 1–186

    Google Scholar 

  • Seeman P (1987)Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152

    Google Scholar 

  • Sonders MS, Keana JEW, Weber E (1988) Phencyclidine and psychotomimetic sigma opiates: recent insight into their biochemical and physiological sites of action. Trends Neurosci 11: 37–40

    Article  PubMed  CAS  Google Scholar 

  • Sokoloff P, Giros B, Martes MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor ( D) as a target of neuroleptics. Nature 347: 146–151

    Google Scholar 

  • Stevens J (1973) An anatomy of schizophrenia. Arch Gen Psychiatry 29: 177–189

    Article  PubMed  CAS  Google Scholar 

  • Taylor DP, Dekleva J (1988) BMY 14802: a potential antipsychotic agent that selectively binds to sigma receptors. In: DOMINO EF, KAMENKA J-M (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 345–355

    Google Scholar 

  • Terenius L, Wahlström A, Lindstrom L, Widerlöv E (1976) Increased CSF levels of endorphins in chronic psychosis. Neurosci Lett 3: 157–162

    Article  PubMed  CAS  Google Scholar 

  • Tom E, LAJrHA A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11: 393–400

    Google Scholar 

  • Tricklebank MD (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 127–129

    Article  PubMed  CAS  Google Scholar 

  • Van Ree JM, Verhoeven WMA, CLAAS FHJ, De Wied D (1986) Antipsychotic action of y-type endorphins: animal and human studies. In: VAN REE JM, Matfhysse S (eds) Progress in brain research, vol 65. Elsevier, Amsterdam, pp 221–235

    Google Scholar 

  • Wadworth AN, Heel RC (1990) Remoxipride. A review of its pharmacodynamie and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40: 863–879

    Google Scholar 

  • Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker F (1988) Evidence for a role of haloperidol-sensitive a-“opiate” receptors in the motor effects of antipsychotic drugs. Neurology 38: 961–965

    Article  PubMed  CAS  Google Scholar 

  • Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355–402

    PubMed  CAS  Google Scholar 

  • Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiatry 23: 210–211

    Google Scholar 

  • Wetzel H, Benkert O (1990) Neuroleptika: Neue Substanzen–neue Indikationen. In: Herz A, HIPPIUS H, Spann W (Hrsg) Psychopharmaka heute. Springer, Berlin Heidelberg New York Tokyo, S 108–128

    Chapter  Google Scholar 

  • Wetzel H, Heuser I, Benkert O (1988) Benzodiazepines for catatonic symptoms, stupor and mutism. Pharmacopsychiatry 21: 394–395

    Article  PubMed  CAS  Google Scholar 

  • Wetzel H, Hillert A, Gründer G (1990) Behandlung der schizophrenen Negativsymptomatik mit Dopamin-Autorezeptor-Agonisten: Erste Erfahrungen mit Roxindol. In: MOLLER HJ, PFIZER E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, 5 231–239

    Google Scholar 

  • Wetzel H, Wiedemann K, Holsboer F, Benkert O (1991) Savoxepine: invalidation of an “atypical” neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 103: 280–283

    Article  PubMed  CAS  Google Scholar 

  • WIDERLÖV E, Lindstrom LH, Besev G, Manberg PJ, Nemeroff CB, Breese GR, Kizer JS, Prange AJ (1982) Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry 139: 1122–1126

    PubMed  Google Scholar 

  • Wiedemann K, Benkert o, Holsboer F (1990) B-HT 920–a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55

    Article  PubMed  CAS  Google Scholar 

  • Wiesel F-A, Farde L, Nordstrom A-L, Sedvall G (1990) Central DI- and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 14: 759–767

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Kornhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer  & Gerd Laux  & 

  2. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Kornhuber, J. (1992). (Potentielle) Antipsychotika mit neuartigen Wirkmechanismen. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3282-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3282-1_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3283-8

  • Online ISBN: 978-3-7091-3282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation